| NCT Number | NCT07247279 |
| Lead Sponsor | AstraZeneca |
| Conditions | Rare Diseases, Generalized Myasthenia Gravis (gMG) |
| Enrollment | 450 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2029-12-31 (estimated) |
| Study Completion | 2029-12-31 (estimated) |
| Updated on ClinicalTrials.gov | 2026-08-12 |